<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Clin. Invest</journal-id>
<journal-id journal-id-type="publisher-id">J Clin Invest</journal-id>
<journal-title-group>
<journal-title>The Journal of Clinical Investigation</journal-title>
</journal-title-group>
<issn pub-type="ppub">0021-9738</issn>
<issn pub-type="epub">1558-8238</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31503551</article-id>
<article-id pub-id-type="pmc">6877328</article-id>
<article-id pub-id-type="publisher-id">129788</article-id>
<article-id pub-id-type="doi">10.1172/JCI129788</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Sonic Hedgehog repression underlies gigaxonin mutation–induced motor deficits in giant axonal neuropathy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Arribat</surname>
<given-names>Yoan</given-names>
</name>
<email>yoan.arribat@unil.ch</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mysiak</surname>
<given-names>Karolina S.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lescouzères</surname>
<given-names>Léa</given-names>
</name>
<email>lea.lescouzeres@inserm.fr</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boizot</surname>
<given-names>Alexia</given-names>
</name>
<email>alexia.boizot@chuv.ch</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ruiz</surname>
<given-names>Maxime</given-names>
</name>
<email>MaximeRuiz@mednet.ucla.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2275-0817</contrib-id>
<name>
<surname>Rossel</surname>
<given-names>Mireille</given-names>
</name>
<email>mireille.rossel@univ-montp2.fr</email>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7216-3261</contrib-id>
<name>
<surname>Bomont</surname>
<given-names>Pascale</given-names>
</name>
<email>pascale.bomont@inserm.fr</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>ATIP-Avenir team, INM, INSERM, University of Montpellier, Montpellier, France.</aff>
<aff id="A2"><label>2</label>MMDN, University of Montpellier, EPHE, INSERM, U1198, PSL Research University, Montpellier, France.</aff>
<author-notes>
<corresp>Address correspondence to: Pascale Bomont, INM-INSERM U1051, Hopital St Eloi, 80 Rue A. Fliche BP 74103, 34091 Montpellier, France. Phone: 33.4.99.63.60.73; Email: <email>pascale.bomont@inserm.fr</email>.</corresp>
<fn>
<p><bold>Authorship note:</bold> YA and KSM are co–first authors and contributed equally to the present work.</p>
</fn>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest:</bold> The authors have declared that no conflict of interest exists.</p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2019-10-28T16:00:00-0400" publication-format="electronic">
<day>28</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date date-type="collection" iso-8601-date="2019-10-28T16:00:00-0400" publication-format="electronic">
<day>28</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date date-type="pub" iso-8601-date="2019-12-02T16:00:00-0500" publication-format="print">
<day>2</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>2</day>
<month>3</month>
<year>2020</year>
</pub-date>
<!-- PMC Release delay is 3 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>129</volume>
<issue>12</issue>
<fpage>5312</fpage>
<lpage>5326</lpage>
<history>
<date date-type="received">
<day>30</day>
<month>4</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>8</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 American Society for Clinical Investigation</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>American Society for Clinical Investigation</copyright-holder>
</permissions>
<self-uri xlink:href="https://www.jci.org/articles/view/129788">This article is available online at https://www.jci.org/articles/view/129788</self-uri>
<abstract>
<p>Growing evidence shows that alterations occurring at early developmental stages contribute to symptoms manifested in adulthood in the setting of neurodegenerative diseases. Here, we studied the molecular mechanisms causing giant axonal neuropathy (GAN), a severe neurodegenerative disease due to loss-of-function of the gigaxonin–E3 ligase. We showed that gigaxonin governs Sonic Hedgehog (Shh) induction, the developmental pathway patterning the dorso-ventral axis of the neural tube and muscles, by controlling the degradation of the Shh-bound Patched receptor. Similar to Shh inhibition, repression of gigaxonin in zebrafish impaired motor neuron specification and somitogenesis and abolished neuromuscular junction formation and locomotion. Shh signaling was impaired in gigaxonin-null zebrafish and was corrected by both pharmacological activation of the Shh pathway and human gigaxonin, pointing to an evolutionary-conserved mechanism regulating Shh signaling. Gigaxonin-dependent inhibition of Shh activation was also demonstrated in primary fibroblasts from patients with GAN and in a Shh activity reporter line depleted in gigaxonin. Our findings establish gigaxonin as a key E3 ligase that positively controls the initiation of Shh transduction, and reveal the causal role of Shh dysfunction in motor deficits, thus highlighting the developmental origin of GAN.</p>
</abstract>
<abstract abstract-type="graphical">
<p>
<graphic orientation="portrait" position="float" xlink:href="jci-129-129788-g115.jpg"></graphic>
</p>
</abstract>
<kwd-group kwd-group-type="specialties">
<kwd>Neuroscience</kwd>
</kwd-group>
<kwd-group kwd-group-type="keywords">
<kwd>Neurodevelopment</kwd>
<kwd>Neuromuscular disease</kwd>
<kwd>Ubiquitin-proteosome system</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>AFM-Téléthon</institution>
<institution-id>https://doi.org/10.13039/501100004923</institution-id>
</institution-wrap>
</funding-source>
<award-id>grant</award-id>
</award-group>
<award-group>
<funding-source>Fondation Maladies Rares</funding-source>
<award-id>grant</award-id>
</award-group>
<award-group>
<funding-source>INSERM</funding-source>
<award-id>ATIP-Avenir</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>AFM-Téléthon</institution>
<institution-id>https://doi.org/10.13039/501100004923</institution-id>
</institution-wrap>
</funding-source>
<award-id>fellowship</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Fondation pour la Recherche Médicale</institution>
<institution-id>https://doi.org/10.13039/501100002915</institution-id>
</institution-wrap>
</funding-source>
<award-id>fellowship</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Fondation pour la Recherche Médicale</institution>
<institution-id>https://doi.org/10.13039/501100002915</institution-id>
</institution-wrap>
</funding-source>
<award-id>fellowship</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Fondation pour la Recherche Médicale</institution>
<institution-id>https://doi.org/10.13039/501100002915</institution-id>
</institution-wrap>
</funding-source>
<award-id>fellowship</award-id>
</award-group>
<funding-statement>#17654</funding-statement>
<funding-statement>#17721</funding-statement>
<funding-statement>#ING20111223593</funding-statement>
<funding-statement>SPF20160936324</funding-statement>
<funding-statement>PLP20170939065</funding-statement>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>